|
1
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: A meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ekbom A, Helmick C, Zack M and Adami HO:
Ulcerative colitis and colorectal cancer. A population-based study.
N Engl J Med. 323:1228–1233. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Claessen MM, Lutgens MW, van Buuren HR,
Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ,
Dijkstra G, van Bodegraven AA, et al: More right-sided
IBD-associated colorectal cancer in patients with primary
sclerosing cholangitis. Inflamm Bowel Dis. 15:1331–1336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gillen CD, Walmsley RS, Prior P, Andrews
HA and Allan RN: Ulcerative colitis and Crohn's disease: A
comparison of the colorectal cancer risk in extensive colitis. Gut.
35:1590–1592. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rutter M, Saunders B, Wilkinson K, Rumbles
S, Schofield G, Kamm M, Williams C, Price A, Talbot I and Forbes A:
Severity of inflammation is a risk factor for colorectal neoplasia
in ulcerative colitis. Gastroenterology. 126:451–459. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winther KV, Jess T, Langholz E, Munkholm P
and Binder V: Long-term risk of cancer in ulcerative colitis: A
population-based cohort study from Copenhagen County. Clin
Gastroenterol Hepatol. 2:1088–1095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kulaylat MN and Dayton MT: Ulcerative
colitis and cancer. J Surg Oncol. 101:706–712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rhodes JM and Campbell BJ: Inflammation
and colorectal cancer: IBD-associated and sporadic cancer compared.
Trends Mol Med. 8:10–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jawad N, Direkze N and Leedham SJ:
Inflammatory bowel disease and colon cancer. Recent Results Cancer
Res. 185:99–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Migheli F and Migliore L: Epigenetics of
colorectal cancer. Clin Genet. 81:312–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stypula-Cyrus Y, Damania D, Kunte DP, Cruz
MD, Subramanian H, Roy HK and Backman V: HDAC up-regulation in
early colon field carcinogenesis is involved in cell tumorigenicity
through regulation of chromatin structure. PLoS One. 8:e646002013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Higashijima J, Kurita N, Miyatani T,
Yoshikawa K, Morimoto S, Nishioka M, Iwata T and Shimada M:
Expression of histone deacetylase 1 and metastasis-associated
protein 1 as prognostic factors in colon cancer. Oncol Rep.
26:343–348. 2011.PubMed/NCBI
|
|
13
|
Wilson AJ, Byun DS, Popova N, Murray LB,
L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH and
Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I
HDACs regulate colon cell maturation and p21 expression and are
deregulated in human colon cancer. J Biol Chem. 281:13548–13558.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Witt O, Deubzer HE, Milde T and Oehme I:
HDAC family: What are the cancer relevant targets? Cancer Lett.
277:8–21. 2009. View Article : Google Scholar
|
|
15
|
Belt EJ, Brosens RP, Delis-van Diemen PM,
Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann
HB, Meijer S, et al: Cell cycle proteins predict recurrence in
stage II and III colon cancer. Ann Surg Oncol. 19(Suppl 3):
S682–S692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Glauben R, Sonnenberg E, Zeitz M and
Siegmund B: HDAC inhibitors in models of inflammation-related
tumorigenesis. Cancer Lett. 280:154–159. 2009. View Article : Google Scholar
|
|
17
|
Khare V, Lyakhovich A, Dammann K, Lang M,
Borgmann M, Tichy B, Pospisilova S, Luciani G, Campregher C,
Evstatiev R, et al: Mesalamine modulates intercellular adhesion
through inhibition of p-21 activated kinase-1. Biochem Pharmacol.
85:234–244. 2013. View Article : Google Scholar :
|
|
18
|
He H, Huynh N, Liu KH, Malcontenti-Wilson
C, Zhu J, Christophi C, Shulkes A and Baldwin GS: P-21 activated
kinase 1 knockdown inhibits β-catenin signalling and blocks
colorectal cancer growth. Cancer Lett. 317:65–71. 2012. View Article : Google Scholar
|
|
19
|
Nassirpour R, Shao L, Flanagan P, Abrams
T, Jallal B, Smeal T and Yin MJ: Nek6 mediates human cancer cell
transformation and is a potential cancer therapeutic target. Mol
Cancer Res. 8:717–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiba T, Marusawa H and Ushijima T:
Inflammation-associated cancer development in digestive organs:
Mechanisms and roles for genetic and epigenetic modulation.
Gastroenterology. 143:550–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feinberg AP, Ohlsson R and Henikoff S: The
epigenetic progenitor origin of human cancer. Nat Rev Genet.
7:21–33. 2006. View Article : Google Scholar
|
|
22
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yi JM, Dhir M, Guzzetta AA,
Iacobuzio-Donahue CA, Heo K, Yang KM, Suzuki H, Toyota M, Kim HM
and Ahuja N: DNA methylation biomarker candidates for early
detection of colon cancer. Tumour Biol. 33:363–372. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Polakis P: The many ways of Wnt in cancer.
Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dammann K, Khare V and Gasche C: Tracing
PAKs from GI inflammation to cancer. Gut. 63:1173–1184. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lagger G, O'Carroll D, Rembold M, Khier H,
Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R,
Jenuwein T, et al: Essential function of histone deacetylase 1 in
proliferation control and CDK inhibitor repression. EMBO J.
21:2672–2681. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU,
Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in
gastric cancer tissues. Jpn J Cancer Res. 92:1300–1304. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyake K, Yoshizumi T, Imura S, Sugimoto
K, Batmunkh E, Kanemura H, Morine Y and Shimada M: Expression of
hypoxia-inducible factor-1alpha, histone deacetylase 1, and
metastasis-associated protein 1 in pancreatic carcinoma:
Correlation with poor prognosis with possible regulation. Pancreas.
36:e1–e9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: A retrospective analysis. Lancet
Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weichert W, Röske A, Gekeler V, Beckers T,
Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M,
et al: Histone deacetylases 1, 2 and 3 are highly expressed in
prostate cancer and HDAC2 expression is associated with shorter PSA
relapse time after radical prostatectomy. Br J Cancer. 98:604–610.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weichert W, Röske A, Niesporek S, Noske A,
Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert
C: Class I histone deacetylase expression has independent
prognostic impact in human colorectal cancer: Specific role of
class I histone deacetylases in vitro and in vivo. Clin Cancer Res.
14:1669–1677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Turgeon N, Blais M, Gagné JM, Tardif V,
Boudreau F, Perreault N and Asselin C: HDAC1 and HDAC2 restrain the
intestinal inflammatory response by regulating intestinal
epithelial cell differentiation. PLoS One. 8:e737852013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marumoto T, Zhang D and Saya H: Aurora-A -
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et
al: A homologue of Drosophila aurora kinase is oncogenic and
amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carvalho B, Postma C, Mongera S, Hopmans
E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A,
Cuesta MA, et al: Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progression.
Gut. 58:79–89. 2009. View Article : Google Scholar
|
|
39
|
Kasap E, Boyacioglu SO, Korkmaz M, Yuksel
ES, Unsal B, Kahraman E, Ozütemiz O and Yuceyar H: Aurora kinase A
(AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes
are upregulated in erosive esophagitis and esophageal
adenocarcinoma. Exp Ther Med. 4:33–42. 2012.PubMed/NCBI
|
|
40
|
Rugge M, Fassan M, Zaninotto G, Pizzi M,
Giacomelli L, Battaglia G, Rizzetto C, Parente P and Ancona E:
Aurora kinase A in Barrett's carcinogenesis. Hum Pathol.
41:1380–1386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Katsha A, Soutto M, Sehdev V, Peng D,
Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y,
et al: Aurora kinase A promotes inflammation and tumorigenesis in
mice and human gastric neoplasia. Gastroenterology.
145:1312–1322.e1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jee HJ, Kim AJ, Song N, Kim HJ, Kim M, Koh
H and Yun J: Nek6 overexpression antagonizes p53-induced senescence
in human cancer cells. Cell Cycle. 9:4703–4710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Belham C, Roig J, Caldwell JA, Aoyama Y,
Kemp BE, Comb M and Avruch J: A mitotic cascade of NIMA family
kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol
Chem. 278:34897–34909. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
O'Regan L and Fry AM: The Nek6 and Nek7
protein kinases are required for robust mitotic spindle formation
and cytokinesis. Mol Cell Biol. 29:3975–3990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cao X, Xia Y, Yang J, Jiang J, Chen L, Ni
R, Li L and Gu Z: Clinical and biological significance of never in
mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell
cancer. Pathol Oncol Res. 18:201–207. 2012. View Article : Google Scholar
|
